China metered dose inhaler market is anticipated to grow at a substantial rate of around 4.0% during the forecast period. High level of air pollution and the significant number of smokers in China is boosting the demand for inhalers in the country. Additionally, the rising geriatric population susceptible to asthma and COPD within the country is also driving the demand for inhalers; thereby, leading to the growth of the metered dose inhaler market in the country. From June 2012 to May 2015, a survey was conducted by the Ministry of Health and Ministry of Science and Technology of China. Around 51,000 citizens participated in the survey with 21,500 men and 29,500 women, according to which, it was estimated that about 100 million adults in 2015 had the problem of COPD in the country. The prevalence is higher in men as compared to women. As per the estimation, there were 68.4 million men and 31.5 million women affected by COPD.
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/china-metered-dose-inhaler-market
China metered dose inhaler market is segmented based on type, application, and end-user. Based on the type, preventive, reliever, and long-acting bronchodilators are analyzed. The preventive inhaler segment led the global metered dose inhaler market in 2018. Preventive inhalers are most widely used in the treatment of asthma in children and adults. These inhalers do not entail side effects for long-term use, and exceptionally decreases the possibility of an asthma exacerbation. The preventive inhalers further reduce the airways swelling and hence, are recommended for regular use by the physician. Some of the preventive inhalers available in the market include Budesonide and Fluticasone. Moreover, based on the application, the market has been classified into asthma and COPD diseases. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed.
Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/china-metered-dose-inhaler-market
Furthermore, the market is characterized by the presence of several manufacturers that are developing and providing metered dose inhalers to cater to a wide range of customers within the Chinese market and across the globe. The major players of the China metered dose inhaler market include Cipla Ltd., Gerresheimer AG, 3M Co., AstraZeneca PLC, Aradigm Corp., Adherium Ltd., GlaxoSmithKline PLC, Novartis AG, ResMed Corp., Teva Pharmaceuticals Industries Ltd., and others. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players. For instance, in July 2019, Cipla Ltd. announced joint-venture (JV) with China-based Jiangsu Acebright Pharma to make respiratory drugs in China. This JV will allow Cipla to expand its footprints in the country and further strengthen its revenue stream.
Market Segmentation
China Metered Dose Inhaler Market by Type
- Preventive Inhaler
- Reliever Inhaler
- Long Acting Bronchodilators Inhaler
China Metered Dose Inhaler Market by Application
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
China Metered Dose Inhaler Market by End-User
- Homecare
- Hospitals and Clinics
Company Profiles
- 3M Co.
- Adherium Ltd.
- Aradigm Corp.
- AstraZeneca PLC
- Boehringer Ingelheim International GmbH
- Cipla Ltd.
- Gerresheimer AG
- GlaxoSmithKline PLC
- Koninklijke Philips N.V.
- Novartis AG
- ResMed Corp.
- Sunovion Pharmaceuticals
- Teva Pharmaceuticals Industries Ltd.
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
